Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Study to Investigate Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of Multiple Doses of the Human GATA-3-specific DNAzyme Solution SB010 in Patients With Mild Allergic Asthma. A Randomised, Double-blind, Parallel, Multicentre, Phase-IIa Study

Next Previous
Trial Profile

Clinical Study to Investigate Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of Multiple Doses of the Human GATA-3-specific DNAzyme Solution SB010 in Patients With Mild Allergic Asthma. A Randomised, Double-blind, Parallel, Multicentre, Phase-IIa Study

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anti-GATA3 gene-therapy (Primary)
  • Indications Allergic asthma; Asthma
  • Focus Proof of concept; Therapeutic Use
  • Sponsors sterna biologicals

Most Recent Events

  • 07 Apr 2017 Results a pre-specified subgroup analysis from this trial were published in the Journal of Allergy and Clinical Immunology 2017, as reported in a Sterna Biologicals Media Release.
  • 07 Apr 2017 Results a pre-specified subgroup analysis published in the Sterna Biologicals Media Release
  • 17 May 2015 According to a Sterna Biologicals media release, full analysis of this trial was presented at the American Thoracic Society (ATS) 2015 International Conference and concurrently, the paper was published in the New England Journal of Medicine (Krug et al., 2015).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top